About The Study: In this randomized double-blind clinical trial of healthy adults administered cannabidiol (CBD), 5 mg/kg/d for 28 days, 8 (5.6%) experienced liver enzyme level elevations and 7 (4.9%) met protocol defined criteria for potential drug-induced liver injury. Participants did not experience clinical symptoms related to liver function during this 28-day study and hepatic enzymes returned to normal within 1 to 2 weeks following discontinuation. The findings of this study underscore the need for further investigation on the long-term effects of CBD use, its impact on various populations, and the safety of lower doses commonly used by consumers.
Corresponding Author: To contact the corresponding author, Jeffry Florian, PhD, email jeffry.florian@fda.hhs.gov .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamainternmed.2025.2366)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2025.2366?guestAccessKey=79997ab2-e714-4534-a34c-b0a63fd074a6&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070725
JAMA Internal Medicine